Sofia Lyme FIA; Sofia 2 Campylobacter FIA
Ortho Clinical Diagnostics Inc. (QuidelOrtho) · Decision date Jul 10, 2026
What did the FDA decide?
FDA records K254295 as a 510(k) premarket notification, with a decision dated Jul 10, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Jul 10, 2026
Regulatory record facts
- Identifier
- K254295
- Regulatory pathway
- 510(k) premarket notification
- Product code
- LSR
- Decision code
- SESE
- Decision date
- Jul 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Reagent, Borrelia Serological Reagent.
- Product code
- LSR
- FDA device class
- 2
FDA decision timeline
K254295 received
Application receipt date recorded by FDA.
K254295 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ortho Clinical Diagnostics Inc. (QuidelOrtho)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Diego, CA
Sources and methodology
- Original FDA record: K254295
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records